Research progress of Dexamethasone intravitreal implants in the treatment of diabetic macular edema
·Diabetic macular edema(DME),a serious complication of diabetic retinopathy(DR),is a chronic condition caused by multiple factors.Throughout its progression,inflammatory factors and vascular endothelial growth factor(VEGF)play a critical role.Anti-VEGF drugs have shown significant effectiveness in the treatment of DME;however,some patients may experience persistent DME after injection or require frequent injections.Dexamethasone intravitreal implants(DEX implants)serve as a sustained-release implant characterized by a reasonable release profile and high bioavailability.They offer safe,effective,and prolonged anti-inflammatory effects,aiding in the repair of retinal barrier and reduction of exudation.To further enhance patients'visual quality,exploring the efficacy of DEX implants in combination with existing treatment regimens has great clinical significance.This review primarily discusses the research advancements in DEX implants,focusing on their pharmacological properties,indications for use,and their combination with existing drugs and treatment methods.It also evaluates the advantages and disadvantages of combination therapy or switching to DEX implants compared to current standard treatments,aiming to provide guidance for personalized treatment options for patients with DME.
万方数据
维普
